Holen Sie sich die Stockscreener-App
1.23
3.15%
-0.04
Vorhandelsmarkt:
1.25
0.02
+1.63%
Schlusskurs vom Vortag:
$1.27
Offen:
$1.26
24-Stunden-Volumen:
4.76M
Relative Volume:
0.74
Marktkapitalisierung:
$382.32M
Einnahmen:
$160.03M
Nettoeinkommen (Verlust:
$-128.58M
KGV:
-2.8819
EPS:
-0.4268
Netto-Cashflow:
$-121.21M
1W Leistung:
+6.96%
1M Leistung:
-9.56%
6M Leistung:
-23.60%
1J Leistung:
-3.15%
1-Tages-Spanne:
$1.22
$1.32
1-Wochen-Bereich:
$1.12
$1.32
52-Wochen-Spanne:
$1.07
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Firmenname
Pacific Biosciences Of California Inc
Sektor
Branche
Telefon
650-521-8000
Adresse
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.23 | 394.76M | 160.03M | -128.58M | -121.21M | -0.4268 |
ABT
Abbott Laboratories
|
114.14 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
327.70 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.30 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.37 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.83 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-06 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-11-11 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-17 | Hochstufung | UBS | Neutral → Buy |
| 2023-10-31 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-06-30 | Eingeleitet | Goldman | Buy |
| 2023-05-10 | Eingeleitet | Barclays | Equal Weight |
| 2023-03-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2023-01-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-21 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-09-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Eingeleitet | Cowen | Outperform |
| 2017-11-03 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Herabstufung | CL King | Buy → Neutral |
| 2016-11-03 | Bestätigt | Cantor Fitzgerald | Buy |
| 2016-06-27 | Eingeleitet | CL King | Buy |
| 2016-04-15 | Eingeleitet | First Analysis Sec | Overweight |
| 2016-02-04 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Bestätigt | Cantor Fitzgerald | Buy |
| 2015-10-23 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-02-04 | Bestätigt | Maxim Group | Buy |
| 2013-09-26 | Bestätigt | Maxim Group | Buy |
| 2013-01-14 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
Pacific (PACB) Earnings Update: EPS Misses Its Estimate on the Day; Trading Response: Shares Close 11.40% Higher in Latest TradingEarnings Weakness Phase - Vinanet
Pacific Biosciences CEO Mark van Oene sells $30,409 in stock By Investing.com - Investing.com South Africa
Pacific Biosciences CEO Mark van Oene sells $30,409 in stock - Investing.com
Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells 26,911 Shares of Stock - MarketBeat
PacBio (NASDAQ: PACB) CEO share sale covers RSU tax withholding - Stock Titan
Pacific Biosciences of California Inc (HAM:P09) Stock Price, Trades & News - GuruFocus
Pacific Biosciences of California Inc (PACB) (Q2 2026) Earnings - GuruFocus
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC Filing (Aug 17, 2026) - Stock Titan
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity - MarketBeat
ARK reports 9.59% stake in Pacific Biosciences (PACB) - Stock Titan
5 Must-Read Analyst Questions From PacBio’s Q2 Earnings Call - Yahoo Finance
PACIFIC BIOSCIENCES (PACB) CEO granted 1.97M options and 489K RSUs - Stock Titan
Measuring – not guessing – the true path - PacBio
Weekly Recap: PACB cuts 2026 revenue guide and Mark Van Oene named CEO - TradingView
Pacific Biosciences of California, Inc. $PACB Shares Sold by Renaissance Technologies LLC - MarketBeat
Pacific Biosciences of California, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PACB) 2026-08-08 - Seeking Alpha
Earnings Release: Here's Why Analysts Cut Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Price Target To US$2.29 - simplywall.st
Pacific Biosciences of California (NASDAQ:PACB) Cut to "Sell" at Wall Street Zen - MarketBeat
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2026: Revenue $39.01M, EPS ($0.14) — 10-Q Summary - TradingView
Pacific Biosciences of California, Inc. Stock 12‑Month Price Target Cut to $2.29, Implies 76% Upside - TradingView
TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3 - Moomoo
PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut - Yahoo Finance
Pacific Biosciences: It's Only Getting Worse (NASDAQ:PACB) - Seeking Alpha
Pacific Biosciences of California Q2 Earnings Call Highlights - TradingView
Pacific Biosciences of California, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Pacific Biosciences of California Appoints New CEO, Plans to Cut 8% of Workforce - Moomoo
Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
PacBio Q2 2026 slides: SPRQ-Nx launch amid revenue miss, cut guidance - Investing.com
Is Pacific Biosciences (PACB) Positioned for Growth After Q2 Ear - GuruFocus
PacBio (NASDAQ:PACB) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings - Barchart.com
Pacific Biosciences of CaliforniaEstimates - Moomoo
PacBio names Mark Van Oene as CEO, replacing Christian Henry By Investing.com - Investing.com South Africa
PACIFIC BIOSCIENCES OF CALIFORNIACHRISTIAN HENRY STEPS DOWN AS PRESIDENT AND CEO - moomoo.com
PacBio Appoints Mark Van Oene as President and Chief Executive Officer - The Manila Times
Pacbio Appoints Mark Van Oene as President an - Moomoo
Pacific Biosciences Announces Restructuring Plan, Cutting 8% of Workforce to Drive Up to $40 Million in Annual Savings by 2027 - marketscreener.com
PacBio Announces Second Quarter 2026 Financial Results - The Manila Times
Press Release: PacBio Appoints Mark Van Oene as President and Chief Executive Officer - Moomoo
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year of 2026 - marketscreener.com
PacBio Vega adds two- and four-hour runs for short-insert DNA - Stock Titan
GenomOncology and PacBio Launch Integrated Oncology Sequencing Workflow - Clinical Lab Products
Pacific Biosciences of California, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
PacBio (PACB) To Report Earnings Tomorrow: Here Is What To Expect - barchart.com
Pacific Biosciences of California Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
PACB5949325 Bond Profile — Key Metrics - TradingView
PACB5949325 Bond Risk Profile - TradingView
PacBio Management Chat Set for Aug. 11 With Live Webcast - Stock Titan
Pacific Biosciences of California Inc (PACB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pacific Biosciences of California Inc (PACB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pacific Biosciences of California, Inc. Revenue Breakdown – NASDAQ:PACB - TradingView
Finanzdaten der Pacific Biosciences Of California Inc-Aktie (PACB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):